These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 28075544)

  • 1. The impact of Type 2 diabetes prevention programmes based on risk-identification and lifestyle intervention intensity strategies: a cost-effectiveness analysis.
    Breeze PR; Thomas C; Squires H; Brennan A; Greaves C; Diggle PJ; Brunner E; Tabak A; Preston L; Chilcott J
    Diabet Med; 2017 May; 34(5):632-640. PubMed ID: 28075544
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Assessing the potential return on investment of the proposed UK NHS diabetes prevention programme in different population subgroups: an economic evaluation.
    Thomas C; Sadler S; Breeze P; Squires H; Gillett M; Brennan A
    BMJ Open; 2017 Aug; 7(8):e014953. PubMed ID: 28827235
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness of Diabetes Prevention Interventions Targeting High-risk Individuals and Whole Populations: A Systematic Review.
    Zhou X; Siegel KR; Ng BP; Jawanda S; Proia KK; Zhang X; Albright AL; Zhang P
    Diabetes Care; 2020 Jul; 43(7):1593-1616. PubMed ID: 33534726
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Economic evaluation of type 2 diabetes prevention programmes: Markov model of low- and high-intensity lifestyle programmes and metformin in participants with different categories of intermediate hyperglycaemia.
    Roberts S; Craig D; Adler A; McPherson K; Greenhalgh T
    BMC Med; 2018 Jan; 16(1):16. PubMed ID: 29378576
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical outcomes and cost-effectiveness of strategies for managing people at high risk for diabetes.
    Eddy DM; Schlessinger L; Kahn R
    Ann Intern Med; 2005 Aug; 143(4):251-64. PubMed ID: 16103469
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness of population-based, community, workplace and individual policies for diabetes prevention in the UK.
    Breeze PR; Thomas C; Squires H; Brennan A; Greaves C; Diggle P; Brunner E; Tabak A; Preston L; Chilcott J
    Diabet Med; 2017 Aug; 34(8):1136-1144. PubMed ID: 28294392
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lifestyle interventions for diabetes mellitus type 2 prevention.
    Sagarra R; Costa B; Cabré JJ; Solà-Morales O; Barrio F;
    Rev Clin Esp (Barc); 2014 Mar; 214(2):59-68. PubMed ID: 24267869
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rationale and design of the PREDICE project: cost-effectiveness of type 2 diabetes prevention among high-risk Spanish individuals following lifestyle intervention in real-life primary care setting.
    Costa B; Cabré JJ; Sagarra R; Solà-Morales O; Barrio F; Piñol JL; Cos X; Bolíbar B; Castell C; Kissimova-Skarbek K; Tuomilehto J;
    BMC Public Health; 2011 Aug; 11():623. PubMed ID: 21831332
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The cost-effectiveness of lifestyle modification or metformin in preventing type 2 diabetes in adults with impaired glucose tolerance.
    Herman WH; Hoerger TJ; Brandle M; Hicks K; Sorensen S; Zhang P; Hamman RF; Ackermann RT; Engelgau MM; Ratner RE;
    Ann Intern Med; 2005 Mar; 142(5):323-32. PubMed ID: 15738451
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness of a lifestyle intervention in high-risk individuals for diabetes in a low- and middle-income setting: Trial-based analysis of the Kerala Diabetes Prevention Program.
    Sathish T; Oldenburg B; Thankappan KR; Absetz P; Shaw JE; Tapp RJ; Zimmet PZ; Balachandran S; Shetty SS; Aziz Z; Mahal A
    BMC Med; 2020 Sep; 18(1):251. PubMed ID: 32883279
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness of the Da Qing diabetes prevention program: A modelling study.
    Hu W; Xu W; Si L; Wang C; Jiang Q; Wang L; Cutler H
    PLoS One; 2020; 15(12):e0242962. PubMed ID: 33382746
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Digitally supported program for type 2 diabetes risk identification and risk reduction in real-world setting: protocol for the StopDia model and randomized controlled trial.
    Pihlajamäki J; Männikkö R; Tilles-Tirkkonen T; Karhunen L; Kolehmainen M; Schwab U; Lintu N; Paananen J; Järvenpää R; Harjumaa M; Martikainen J; Kohl J; Poutanen K; Ermes M; Absetz P; Lindström J; Lakka TA;
    BMC Public Health; 2019 Mar; 19(1):255. PubMed ID: 30823909
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of lifestyle changes on adults with prediabetes: A systematic review and meta-analysis.
    Glechner A; Keuchel L; Affengruber L; Titscher V; Sommer I; Matyas N; Wagner G; Kien C; Klerings I; Gartlehner G
    Prim Care Diabetes; 2018 Oct; 12(5):393-408. PubMed ID: 30076075
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Economic evaluation of a lifestyle intervention in primary care to prevent type 2 diabetes mellitus and cardiovascular diseases: a randomized controlled trial.
    van Wier MF; Lakerveld J; Bot SD; Chinapaw MJ; Nijpels G; van Tulder MW
    BMC Fam Pract; 2013 Apr; 14():45. PubMed ID: 23557482
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Implementing Lifestyle Change Interventions to Prevent Type 2 Diabetes in US Medicaid Programs: Cost Effectiveness, and Cost, Health, and Health Equity Impact.
    Laxy M; Zhang P; Ng BP; Shao H; Ali MK; Albright A; Gregg EW
    Appl Health Econ Health Policy; 2020 Oct; 18(5):713-726. PubMed ID: 32607728
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness of statins for primary prevention in patients newly diagnosed with type 2 diabetes in the Netherlands.
    de Vries FM; Denig P; Visser ST; Hak E; Postma MJ
    Value Health; 2014 Mar; 17(2):223-30. PubMed ID: 24636380
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Selecting the optimal risk threshold of diabetes risk scores to identify high-risk individuals for diabetes prevention: a cost-effectiveness analysis.
    Mühlenbruch K; Zhuo X; Bardenheier B; Shao H; Laxy M; Icks A; Zhang P; Gregg EW; Schulze MB
    Acta Diabetol; 2020 Apr; 57(4):447-454. PubMed ID: 31745647
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting of the diabetes prevention program leads to substantial benefits when capacity is constrained.
    Olchanski N; van Klaveren D; Cohen JT; Wong JB; Ruthazer R; Kent DM
    Acta Diabetol; 2021 Jun; 58(6):707-722. PubMed ID: 33517494
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of a social prescribing intervention in North East England on adults with type 2 diabetes: the SPRING_NE multimethod study.
    Moffatt S; Wildman J; Pollard TM; Gibson K; Wildman JM; O'Brien N; Griffith B; Morris SL; Moloney E; Jeffries J; Pearce M; Mohammed W
    Public Health Res (Southampt); 2023 Mar; 11(2):1-185. PubMed ID: 37254700
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.